Premium
Improvement of Monoclonal Antibody Production in Hybridoma Cells by Dimethyl Sulfoxide
Author(s) -
Ling Wai Lam W.,
Deng Liang,
Lepore Joseph,
Cutler Collette,
CanCarlson Susan,
Wang Yan,
Voloch Marcio
Publication year - 2003
Publication title -
biotechnology progress
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.572
H-Index - 129
eISSN - 1520-6033
pISSN - 8756-7938
DOI - 10.1021/bp020068d
Subject(s) - dimethyl sulfoxide , monoclonal antibody , clone (java method) , titer , chemistry , cell culture , microbiology and biotechnology , hybridoma technology , antibody , biochemistry , biology , immunology , organic chemistry , gene , genetics
Hybridoma cultures are routinely used as a source for monoclonal antibody (mAb) production necessary for preclinical evaluation. However, these cultures typically have low volumetric and specific productivities. In this article, we examined the use and the timing of addition of dimethyl sulfoxide (DMSO) as a medium additive to improve mAb production in our hybridoma clone 19 (c19) cultures. From shake flask studies, we defined the optimal DMSO concentration and time of addition for improved productivity. This timing coordinated with high cell viability and density. Hybridoma cultures treated with DMSO up to 0.3% (v/v) possessed cell densities and viabilities comparable to untreated control. We demonstrated that 0.2% (v/v) DMSO added to shake flask cultures at their maximal viable cell densities resulted in a 2‐fold increase in specific mAb production. This procedure was scaleable up to 20 L Cellbags (Wave Bioreactors) with similar titer improvement. Moreover, DMSO treatment did not affect the bioactivity or glycosylation profiles of the mAb.